Levovar

Carbidopa/Levodopa, the active ingredient in Levovar, is an Antiparkinson agent presented as an oral tablet for oral use. It is employed to manage the motor symptoms of Parkinson's disease and related Parkinsonian syndromes by restoring central dopamine levels.

GNH USA supplies Levovar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global distribution network ensures timely delivery and compliance with local regulatory requirements.

Carbidopa/Levodopa acts on the dopaminergic pathway and is indicated for Parkinsonian motor disorders.

Parkinson's disease: improves bradykinesia, rigidity, and tremor, enhancing functional mobility. Parkinsonian syndrome: alleviates motor symptoms in secondary parkinsonism such as drug‑induced or vascular causes. Levodopa‑responsive motor fluctuations: reduces off‑periods and stabilizes symptom control in patients with advanced disease.

Carbidopa/Levodopa may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension

Serious or Rare Side Effects: - Psychosis or hallucinations - Severe hypotension or syncope - Dyskinesia (involuntary movements)

When using Levovar, several precautions should be observed to minimise risk.

Dose titration: start with low dose and increase gradually under medical supervision. Monitor for dyskinesia: watch for involuntary movements as therapy progresses. Assess cardiovascular status: patients with heart disease may be prone to hypotension. Avoid abrupt discontinuation: sudden stop can precipitate worsening of Parkinsonian symptoms. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at room temperature: keep in the original container, protect from moisture and light.

Carbidopa/Levodopa interacts with several medicines; awareness helps avoid adverse outcomes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors (e.g., phenelzine): risk of hypertensive crisis. - Antipsychotics that block dopamine receptors (e.g., haloperidol): may diminish therapeutic effect. - Pyridoxine (vitamin B6) at high doses: accelerates peripheral levodopa metabolism.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering effect. - Selective serotonin reuptake inhibitors (SSRIs): may increase risk of serotonin syndrome. - Other antiparkinson drugs (e.g., selegiline): may require dose adjustment.